Board/Management Information • Oct 9, 2014
Board/Management Information
Open in ViewerOpens in native device viewer
Strasbourg, France, October 9, 2014 – Transgene SA (NYSE-Euronext: TNG) announced today the further strengthening of its management team following the recent arrival of Eric Quémeneur as Executive Vice President, Vice President Research & Development. The management committee of Transgene, chaired by Philippe Archinard, Chairman and Chief Executive Officer, is now composed of: Eric Quémeneur; Dr Nathalie Adda, Vice President, Chief Medical Officer; Christophe Ancel, Vice President Quality and Qualified Person; Jean-Philippe Del, Vice President Finance; Thibaut du Fayet, Vice President Alliance Management, Project Management and Marketing; Colin Freund, Vice President Business Development; Patrick Mahieux, Vice President Industrial and Pharmaceutical Operations; and Hemanshu Shah, Vice President Medical Affairs. Stéphane Boissel, Executive Vice President and Chief Financial Officer, announced that he is leaving the Company to pursue other opportunities.
Philippe Archinard, Chairman and Chief Executive Officer, said: "With this new management committee, Transgene now has a transatlantic management team of talented and experienced managers able to execute the next important phases of the Company's development. I wish to thank Stéphane for the positive contributions he has made to the organization and development of Transgene during the past four years and wish him well in his future endeavours."
Transgene (NYSE-Euronext: TNG), a member of the Institut Mérieux Group, is a publicly traded French biopharmaceutical company focused on discovering, developing and manufacturing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene's programs utilize well-tolerated viruses with the goal of indirectly or directly killing infected or cancerous cells. The Company's two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The Company has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S. Additional information about Transgene is available at www.transgene.fr.
Transgene Elisabetta Castelli, Director Investor Relations +33 (0)3 88 27 91 21 Laurie Doyle, Director Investor Relations US & Corporate Communications +1 (339) 832 0752 MC Services Raimund Gabriel +49 89 210 228 30 [email protected] Shaun Brown +44 207 148 5998 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.